Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × DLL3 protein, human × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Everolimus 9 Cisplatin 7 Temozolomide 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Nivolumab 4 Etoposide 4 Carboplatin 4 Capecitabine 4 Irinotecan 3 sintilimab 2 pembrolizumab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06893783 2025-09-08

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡